The sharp revenue acceleration, especially in Q4, combined with the Corstasis acquisition and narrowing losses, suggests improving fundamentals and strategic expansion. Traders should monitor U.S. prescription growth trends, integration of Enbumyst™, and progress on triple-combination therapies expected in 2027.
ESPR drugs
ESPR drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 10 $2.70entry
- T+1 · 8mo ago −4.07%α −3.97% · $2.59
- T+5 · 8mo ago +0.37%α +1.28% · $2.71
- T+20 · 7mo ago −13.70%α −13.55% · $2.33
- T+60 · 6mo ago +16.30%α +4.61% · $3.14
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Esperion Therapeutics reported strong financial results for Q4 and full-year 2025, with total revenue growing 144% YoY in Q4 to $168.4 million and 21% for the full year to $403.1 million. U.S. net product revenue grew 38% YoY in both periods, driven by bempedoic acid franchise momentum. The company also announced an acquisition of Corstasis Therapeutics to expand its cardiovascular portfolio with Enbumyst™, a nasal spray diuretic for heart failure patients.
Key Financial Metrics
Key Facts
- Q4 2025 total revenue grew 144% YoY to $168.4 million; full-year 2025 revenue grew 21% to $403.1 million
- Q4 U.S. net product revenue grew ~38% YoY to $43.7 million; full-year U.S. net product revenue grew 38% to $159.6 million
- Q4 retail prescription equivalents grew 34% YoY and 11.3% Q/Q
- Net income of $61.8 million in Q4 2025 vs. net loss of $21.3 million in Q4 2024
- Full-year 2025 net loss narrowed to $22.7 million from $51.7 million in 2024
- Acquired Corstasis Therapeutics to add Enbumyst™, a first-in-class nasal spray diuretic for CHF, hepatic, and renal edema
- Cash and cash equivalents increased to $167.9 million from $144.8 million in 2024
- Otsuka partnership in Japan triggered a $90 million payment to Esperion
Financial Impact
Q4 revenue more than doubled YoY with $168.4M vs. $69.1M; full-year revenue up $70.8M YoY. Net loss cut by over 56% despite R&D and SG&A increases. $90M one-time payment from Japan significantly boosted collaboration revenue.
Risk Factors
- Future profitability depends on sustaining U.S. prescription growth and payer coverage
- Integration risk from Corstasis acquisition and execution on new pipeline candidates
- Dependence on international partners for royalty revenue; fluctuations possible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252553 |
Track record
21 reports on ESPR
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +7.56% at T+60 after the Mar 3, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers